Track topics on Twitter Track topics that are important to you
NEW YORK (Reuters) - Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."
Original Article: Health insurer Anthem eases restrictions on Sarepta's Duchenne treatmentNEXT ARTICLE
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...